Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants.

Pecquet C, Chachoua I, Roy A, Balligand T, Vertenoeil G, Leroy E, Albu RI, Defour JP, Nivarthi H, Hug E, Xu E, Ould-Amer Y, Mouton C, Colau D, Vertommen D, Shwe MM, Marty C, Plo I, Vainchenker W, Kralovics R, Constantinescu SN.

Blood. 2019 Jun 20;133(25):2669-2681. doi: 10.1182/blood-2018-09-874578. Epub 2019 Mar 22.

PMID:
30902807
2.

Differential effect of inhibitory strategies of the V617 mutant of JAK2 on cytokine receptor signaling.

Leroy E, Balligand T, Pecquet C, Mouton C, Colau D, Shiau AK, Dusa A, Constantinescu SN.

J Allergy Clin Immunol. 2019 Jul;144(1):224-235. doi: 10.1016/j.jaci.2018.12.1023. Epub 2019 Jan 29.

PMID:
30707971
3.

Propeptide glycosylation and galectin-3 binding decrease proteolytic activation of human proMMP-9/progelatinase B.

Boon L, Ugarte-Berzal E, Martens E, Vandooren J, Rybakin V, Colau D, Gordon-Alonso M, van der Bruggen P, Stöcker W, Becker-Pauly C, Witters P, Morava E, Jaeken J, Proost P, Opdenakker G.

FEBS J. 2019 Mar;286(5):930-945. doi: 10.1111/febs.14698. Epub 2018 Nov 30.

PMID:
30422384
4.

Structural basis of latent TGF-β1 presentation and activation by GARP on human regulatory T cells.

Liénart S, Merceron R, Vanderaa C, Lambert F, Colau D, Stockis J, van der Woning B, De Haard H, Saunders M, Coulie PG, Savvides SN, Lucas S.

Science. 2018 Nov 23;362(6417):952-956. doi: 10.1126/science.aau2909. Epub 2018 Oct 25.

PMID:
30361387
5.

Combination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against P815 mastocytoma.

Lopes A, Vanvarenberg K, Kos Š, Lucas S, Colau D, Van den Eynde B, Préat V, Vandermeulen G.

Sci Rep. 2018 Oct 24;8(1):15732. doi: 10.1038/s41598-018-33933-7.

6.

Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes.

Zhu J, Powis de Tenbossche CG, Cané S, Colau D, van Baren N, Lurquin C, Schmitt-Verhulst AM, Liljeström P, Uyttenhove C, Van den Eynde BJ.

Nat Commun. 2017 Nov 10;8(1):1404. doi: 10.1038/s41467-017-00784-1.

7.

Blocking immunosuppression by human Tregs in vivo with antibodies targeting integrin αVβ8.

Stockis J, Liénart S, Colau D, Collignon A, Nishimura SL, Sheppard D, Coulie PG, Lucas S.

Proc Natl Acad Sci U S A. 2017 Nov 21;114(47):E10161-E10168. doi: 10.1073/pnas.1710680114. Epub 2017 Nov 6.

8.

Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8+ T cells.

Hanoteau A, Henin C, Svec D, Bisilliat Donnet C, Denanglaire S, Colau D, Romero P, Leo O, Van den Eynde B, Moser M.

Oncoimmunology. 2017 May 11;6(8):e1318234. doi: 10.1080/2162402X.2017.1318234. eCollection 2017.

9.

Identification of a naturally processed HLA-A*02:01-restricted CTL epitope from the human tumor-associated antigen Nectin-4.

Lopez M, Ghidouche A, Rochas C, Godelaine D, Carrasco J, Colau D, Hames G, Montero-Julian FA, Coulie PG, Olive D.

Cancer Immunol Immunother. 2016 Oct;65(10):1177-88. doi: 10.1007/s00262-016-1877-7. Epub 2016 Aug 11.

PMID:
27514672
10.

CD8 T-cell responses against the immunodominant Theileria parva peptide Tp249-59 are composed of two distinct populations specific for overlapping 11-mer and 10-mer epitopes.

Connelley TK, Li X, MacHugh N, Colau D, Graham SP, van der Bruggen P, Taracha EL, Gill A, Morrison WI.

Immunology. 2016 Oct;149(2):172-85. doi: 10.1111/imm.12637. Epub 2016 Jul 25.

11.

Uncoupling JAK2 V617F activation from cytokine-induced signalling by modulation of JH2 αC helix.

Leroy E, Dusa A, Colau D, Motamedi A, Cahu X, Mouton C, Huang LJ, Shiau AK, Constantinescu SN.

Biochem J. 2016 Jun 1;473(11):1579-91. doi: 10.1042/BCJ20160085. Epub 2016 Mar 30.

12.

Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo.

Cuende J, Liénart S, Dedobbeleer O, van der Woning B, De Boeck G, Stockis J, Huygens C, Colau D, Somja J, Delvenne P, Hannon M, Baron F, Dumoutier L, Renauld JC, De Haard H, Saunders M, Coulie PG, Lucas S.

Sci Transl Med. 2015 Apr 22;7(284):284ra56. doi: 10.1126/scitranslmed.aaa1983.

13.

Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.

Röhrig UF, Majjigapu SR, Chambon M, Bron S, Pilotte L, Colau D, Van den Eynde BJ, Turcatti G, Vogel P, Zoete V, Michielin O.

Eur J Med Chem. 2014 Sep 12;84:284-301. doi: 10.1016/j.ejmech.2014.06.078. Epub 2014 Jul 10.

PMID:
25036789
14.

Absence of recognition of common melanocytic antigens by T cells isolated from the cerebrospinal fluid of a Vogt-Koyanagi-Harada patient.

Abad S, Wieërs G, Colau D, Wildmann C, Delair E, Dhote R, Brézin AP, Kawakami Y, Coulie PG, van der Bruggen P.

Mol Vis. 2014 Jul 2;20:956-69. eCollection 2014.

15.

Cyclophosphamide treatment induces rejection of established P815 mastocytoma by enhancing CD4 priming and intratumoral infiltration of P1E/H-2K(d) -specific CD8+ T cells.

Rahir G, Wathelet N, Hanoteau A, Henin C, Oldenhove G, Galuppo A, Lanaya H, Colau D, Mackay CR, Van den Eynde B, Moser M.

Int J Cancer. 2014 Jun 15;134(12):2841-52. doi: 10.1002/ijc.28617. Epub 2013 Nov 29.

16.

Analysis of the processing of seven human tumor antigens by intermediate proteasomes.

Guillaume B, Stroobant V, Bousquet-Dubouch MP, Colau D, Chapiro J, Parmentier N, Dalet A, Van den Eynde BJ.

J Immunol. 2012 Oct 1;189(7):3538-47. Epub 2012 Aug 27.

17.

Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxygenase 1 inhibition.

Röhrig UF, Majjigapu SR, Grosdidier A, Bron S, Stroobant V, Pilotte L, Colau D, Vogel P, Van den Eynde BJ, Zoete V, Michielin O.

J Med Chem. 2012 Jun 14;55(11):5270-90. doi: 10.1021/jm300260v. Epub 2012 May 22.

PMID:
22616902
18.

Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase.

Pilotte L, Larrieu P, Stroobant V, Colau D, Dolusic E, Frédérick R, De Plaen E, Uyttenhove C, Wouters J, Masereel B, Van den Eynde BJ.

Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2497-502. doi: 10.1073/pnas.1113873109. Epub 2012 Jan 30.

19.

Minimal tolerance to a tumor antigen encoded by a cancer-germline gene.

Huijbers IJ, Soudja SM, Uyttenhove C, Buferne M, Inderberg-Suso EM, Colau D, Pilotte L, Powis de Tenbossche CG, Chomez P, Brasseur F, Schmitt-Verhulst AM, Van den Eynde BJ.

J Immunol. 2012 Jan 1;188(1):111-21. doi: 10.4049/jimmunol.1002612. Epub 2011 Dec 2.

20.

Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators.

Dolusić E, Larrieu P, Moineaux L, Stroobant V, Pilotte L, Colau D, Pochet L, Van den Eynde B, Masereel B, Wouters J, Frédérick R.

J Med Chem. 2011 Aug 11;54(15):5320-34. doi: 10.1021/jm2006782. Epub 2011 Jul 18.

PMID:
21726069
21.

Discovery and preliminary SARs of keto-indoles as novel indoleamine 2,3-dioxygenase (IDO) inhibitors.

Dolušić E, Larrieu P, Blanc S, Sapunaric F, Pouyez J, Moineaux L, Colette D, Stroobant V, Pilotte L, Colau D, Ferain T, Fraser G, Galleni M, Frère JM, Masereel B, Van den Eynde B, Wouters J, Frédérick R.

Eur J Med Chem. 2011 Jul;46(7):3058-65. doi: 10.1016/j.ejmech.2011.02.049. Epub 2011 Feb 26.

22.

Indol-2-yl ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitors.

Dolušić E, Larrieu P, Blanc S, Sapunaric F, Norberg B, Moineaux L, Colette D, Stroobant V, Pilotte L, Colau D, Ferain T, Fraser G, Galleni M, Frère JM, Masereel B, Van den Eynde B, Wouters J, Frédérick R.

Bioorg Med Chem. 2011 Feb 15;19(4):1550-61. doi: 10.1016/j.bmc.2010.12.032. Epub 2010 Dec 16. Erratum in: Bioorg Med Chem. 2011 May 1;19(9):3029. Galeni, Moreno [corrected to Galleni, Moreno].

23.

3D systems delivering VEGF to promote angiogenesis for tissue engineering.

des Rieux A, Ucakar B, Mupendwa BP, Colau D, Feron O, Carmeliet P, Préat V.

J Control Release. 2011 Mar 30;150(3):272-8. doi: 10.1016/j.jconrel.2010.11.028. Epub 2010 Dec 3.

PMID:
21130820
24.

Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules.

Guillaume B, Chapiro J, Stroobant V, Colau D, Van Holle B, Parvizi G, Bousquet-Dubouch MP, Théate I, Parmentier N, Van den Eynde BJ.

Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18599-604. doi: 10.1073/pnas.1009778107. Epub 2010 Oct 11.

25.

Production of an antigenic peptide by insulin-degrading enzyme.

Parmentier N, Stroobant V, Colau D, de Diesbach P, Morel S, Chapiro J, van Endert P, Van den Eynde BJ.

Nat Immunol. 2010 May;11(5):449-54. doi: 10.1038/ni.1862. Epub 2010 Apr 4.

PMID:
20364150
26.

Rational design of indoleamine 2,3-dioxygenase inhibitors.

Röhrig UF, Awad L, Grosdidier A, Larrieu P, Stroobant V, Colau D, Cerundolo V, Simpson AJ, Vogel P, Van den Eynde BJ, Zoete V, Michielin O.

J Med Chem. 2010 Feb 11;53(3):1172-89. doi: 10.1021/jm9014718.

PMID:
20055453
27.

Membrane protein GARP is a receptor for latent TGF-beta on the surface of activated human Treg.

Stockis J, Colau D, Coulie PG, Lucas S.

Eur J Immunol. 2009 Dec;39(12):3315-22. doi: 10.1002/eji.200939684.

28.

The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells.

François V, Ottaviani S, Renkvist N, Stockis J, Schuler G, Thielemans K, Colau D, Marchand M, Boon T, Lucas S, van der Bruggen P.

Cancer Res. 2009 May 15;69(10):4335-45. doi: 10.1158/0008-5472.CAN-08-3726. Epub 2009 May 12.

29.

Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.

Bonehill A, Van Nuffel AM, Corthals J, Tuyaerts S, Heirman C, François V, Colau D, van der Bruggen P, Neyns B, Thielemans K.

Clin Cancer Res. 2009 May 15;15(10):3366-75. doi: 10.1158/1078-0432.CCR-08-2982. Epub 2009 May 5.

30.

Crystal structure of a soluble decoy receptor IL-22BP bound to interleukin-22.

de Moura PR, Watanabe L, Bleicher L, Colau D, Dumoutier L, Lemaire MM, Renauld JC, Polikarpov I.

FEBS Lett. 2009 Apr 2;583(7):1072-7. doi: 10.1016/j.febslet.2009.03.006. Epub 2009 Mar 11.

31.

Crystallization and preliminary X-ray diffraction analysis of human IL-22 bound to its soluble decoy receptor IL-22BP.

Watanabe L, de Moura PR, Nascimento AS, Colau D, Dumoutier L, Renauld JC, Polikarpov I.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2009 Feb 1;65(Pt 2):102-4. doi: 10.1107/S1744309108042309. Epub 2009 Jan 7.

32.

Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients.

Fontana R, Bregni M, Cipponi A, Raccosta L, Rainelli C, Maggioni D, Lunghi F, Ciceri F, Mukenge S, Doglioni C, Colau D, Coulie PG, Bordignon C, Traversari C, Russo V.

Blood. 2009 Feb 19;113(8):1651-60. doi: 10.1182/blood-2008-07-168666. Epub 2008 Dec 12.

33.

The zinc center influences the redox and thermodynamic properties of Escherichia coli thioredoxin 2.

El Hajjaji H, Dumoulin M, Matagne A, Colau D, Roos G, Messens J, Collet JF.

J Mol Biol. 2009 Feb 13;386(1):60-71. doi: 10.1016/j.jmb.2008.11.046. Epub 2008 Dec 3.

PMID:
19073194
34.

Crystal structure of the IL-22/IL-22R1 complex and its implications for the IL-22 signaling mechanism.

Bleicher L, de Moura PR, Watanabe L, Colau D, Dumoutier L, Renauld JC, Polikarpov I.

FEBS Lett. 2008 Sep 3;582(20):2985-92. doi: 10.1016/j.febslet.2008.07.046. Epub 2008 Aug 7.

35.

Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes.

Demotte N, Stroobant V, Courtoy PJ, Van Der Smissen P, Colau D, Luescher IF, Hivroz C, Nicaise J, Squifflet JL, Mourad M, Godelaine D, Boon T, van der Bruggen P.

Immunity. 2008 Mar;28(3):414-24. doi: 10.1016/j.immuni.2008.01.011.

36.

Interleukin-22 forms dimers that are recognized by two interleukin-22R1 receptor chains.

de Oliveira Neto M, Ferreira JR Jr, Colau D, Fischer H, Nascimento AS, Craievich AF, Dumoutier L, Renauld JC, Polikarpov I.

Biophys J. 2008 Mar 1;94(5):1754-65. Epub 2007 Nov 16.

37.

Nucleophosmin leukaemic mutants contain C-terminus peptides that bind HLA class I molecules.

Liso A, Colau D, Benmaamar R, De Groot A, Martin W, Benedetti R, Specchia G, Martelli MP, Coulie P, Falini B.

Leukemia. 2008 Feb;22(2):424-6. Epub 2007 Aug 9. No abstract available.

PMID:
17690700
38.

Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor.

Näslund TI, Uyttenhove C, Nordström EK, Colau D, Warnier G, Jondal M, Van den Eynde BJ, Liljeström P.

J Immunol. 2007 Jun 1;178(11):6761-9.

39.

Lack of tumor recognition by cytolytic T lymphocyte clones recognizing peptide 195-203 encoded by gene MAGE-A3 and presented by HLA-A24 molecules.

So T, Hanagiri T, Chapiro J, Colau D, Brasseur F, Yasumoto K, Boon T, Coulie PG.

Cancer Immunol Immunother. 2007 Feb;56(2):259-69. Epub 2006 Jun 7.

PMID:
16758204
40.

Identification of effector-memory CMV-specific T lymphocytes that kill CMV-infected target cells in an HLA-E-restricted fashion.

Mazzarino P, Pietra G, Vacca P, Falco M, Colau D, Coulie P, Moretta L, Mingari MC.

Eur J Immunol. 2005 Nov;35(11):3240-7.

41.

A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors.

Sun Z, Lethé B, Zhang Y, Russo V, Colau D, Stroobant V, Boon T, van der Bruggen P.

Cancer Immunol Immunother. 2006 Jun;55(6):644-52. Epub 2005 Sep 27.

PMID:
16187088
42.

A new MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A24 carcinoma cells.

Ottaviani S, Colau D, van der Bruggen P, van der Bruggen P.

Cancer Immunol Immunother. 2006 Jul;55(7):867-72. Epub 2005 Sep 3.

PMID:
16151806
43.

A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.

Zhang Y, Renkvist N, Sun Z, Schuler-Thurner B, Glaichenhaus N, Schuler G, Boon T, van der Bruggen P, Colau D.

Eur J Immunol. 2005 Apr;35(4):1066-75.

44.

Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen.

Lonchay C, van der Bruggen P, Connerotte T, Hanagiri T, Coulie P, Colau D, Lucas S, Van Pel A, Thielemans K, van Baren N, Boon T.

Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14631-8. Epub 2004 Sep 27.

45.

New MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A1 tumor cells.

Kobayashi T, Lonchay C, Colau D, Demotte N, Boon T, van der Bruggen P.

Tissue Antigens. 2003 Nov;62(5):426-32.

PMID:
14617050
46.

Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus.

Karanikas V, Lurquin C, Colau D, van Baren N, De Smet C, Lethé B, Connerotte T, Corbière V, Demoitié MA, Liénard D, Dréno B, Velu T, Boon T, Coulie PG.

J Immunol. 2003 Nov 1;171(9):4898-904.

47.

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.

Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ.

Nat Med. 2003 Oct;9(10):1269-74. Epub 2003 Sep 21.

PMID:
14502282
48.

Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.

Coulie PG, Karanikas V, Lurquin C, Colau D, Connerotte T, Hanagiri T, Van Pel A, Lucas S, Godelaine D, Lonchay C, Marchand M, Van Baren N, Boon T.

Immunol Rev. 2002 Oct;188:33-42. Review.

PMID:
12445279
49.

A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes.

Schiavetti F, Thonnard J, Colau D, Boon T, Coulie PG.

Cancer Res. 2002 Oct 1;62(19):5510-6.

50.

TNF-mediated toxicity after massive induction of specific CD8+ T cells following immunization of mice with a tumor-specific peptide.

Bilsborough J, Uyttenhove C, Colau D, Bousso P, Libert C, Weynand B, Boon T, van den Eynde BJ.

J Immunol. 2002 Sep 15;169(6):3053-60.

Supplemental Content

Support Center